학술논문
Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
Original Research
tumor necrosis factor, Hacettepe University Biologic
Original Research
tumor necrosis factor, Hacettepe University Biologic
Document Type
Report
Author
Duran, Emine; Ozturk, Zeynep Ozge; Bilgin, Emre; Büyükasik, Yahya; Dizdar, Omer; Yardimci, Gozde Kubra; Farisogullari, Bayram; Ozsoy, Zehra; Ayan, Gizem; Uzun, Gullu Sandal; Ekici, Mustafa; Unaldi, Erdinc; Kilic, Levent; Akdogan, Ali; Karadag, Omer; Bilgen, Sule Apras; Kiraz, Sedat; Kalyoncu, Umut; Ertenli, Ali Ihsan
Source
Rheumatology and Therapy. August 2023, Vol. 10 Issue 4, p969, 13 p.
Subject
Language
English
Abstract
Author(s): Emine Duran [sup.1] , Zeynep Ozge Ozturk [sup.2] , Emre Bilgin [sup.1] , Yahya Büyükasik [sup.3] , Omer Dizdar [sup.4] , Gozde Kubra Yardimci [sup.1] , Bayram Farisogullari [sup.1] [...]
Introduction This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. Methods HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR). Results Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26-67), and the median age at the HM diagnosis was 55.5 (range, 38-76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35-7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55). Conclusions The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.
Introduction This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. Methods HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR). Results Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26-67), and the median age at the HM diagnosis was 55.5 (range, 38-76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35-7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55). Conclusions The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.